Non-homologous end joining in class switch recombination: the beginning of the end by Kotnis, Ashwin et al.
Review
Non-homologous end joining in class switch
recombination: the beginning of the end
Ashwin Kotnis, Likun Du, Chonghai Liu, Sergey W. Popov
and Qiang Pan-Hammarstro ¨m*
Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska
University Hospital Huddinge, 14186 Stockholm, Sweden
Immunoglobulin class switch recombination (CSR) is initiated by a B-cell-speciﬁc factor, activation-
induced deaminase, probably through deamination of deoxycytidine residues within the switch (S)
regions. The initial lesions in the S regions are subsequently processed, resulting in the production of
DNA double-strand breaks (DSBs). These breaks will then be recognized, edited and repaired,
ﬁnally leading to the recombination of the two S regions. Two major repair pathways have been
implicated in CSR, the predominant non-homologous end joining (NHEJ) and the alternative end-
joining (A-EJ) pathways. The former requires not only components of the ‘classical’ NHEJ
machinery, i.e. Ku70/Ku80, DNA-dependent protein kinase catalytic subunit, DNA ligase IV and
XRCC4, but also a number of DNA-damage sensors or adaptors, such as ataxia–telangiectasia
mutated, gH2AX, 53BP1, MDC1, the Mre11–Rad50–NBS1 complex and the ataxia telangiectasia
and Rad3-related protein (ATR). The latter pathway is not well characterized yet and probably
requires microhomologies. In this review, we will focus on the current knowledge of the predominant
NHEJ pathway in CSR and will also give a perspective on the A-EJ pathway.
Keywords: class switch recombination; non-homologous end joining; alternative NHEJ;
microhomology
1. INTRODUCTION
Immunoglobulin M (IgM) is the primordial antibody
class and has been supplemented during evolution by
antibody classes (IgG, IgA and IgE) with improved,
more specialized, effector functions. The change in
antibody class is effectuated by a looping out–
deletion–recombination process called class switch
recombination (CSR), where the constant region
gene of the m heavy chain (Cm) is replaced by a
downstream constant region gene (Cg, Ca or C3;
Stavnezer et al. 2008). The process requires germ line
(GL) transcription of the unrearranged C region genes
(Stavnezer 1996; Chaudhuri & Alt 2004)a n di s
initiated by a B-cell-speciﬁc factor, activation-induced
cytidine deaminase (AID; Muramatsu et al. 2000; Revy
et al. 2000). The modes of action of AID are discussed
elsewhere in this issue.
CSR involves DNA regions, called ‘switch (S)
regions’, that are located in the introns upstream of
each C region gene, except Cd. S regions are composed
of tandemly repeated sequences that contain common
pentameric sequences (GAGCT and GGGCT), but
differ in the overall length of the repetitive region, the
actual sequence of the repeats and the number of
polymorphic alleles (Pan-Hammarstrom et al. 2007).
In both humans and mice, Sm,S a and S3 are closely
related and characterized by a dense clustering
of pentameric repeats, with or without a higher
ordered structure. The Sg regions, however, share
very little homology with the respective Sm regions
(Pan-Hammarstrom et al. 2007).
The initial lesions introduced by AID in the S
regions are subsequently processed, leading to the
production of DNA double-strand breaks (DSBs;
discussed elsewhere in this issue). There are two
major mechanisms for the repair of DSBs, homologous
recombination (HR) and non-homologous end joining
(NHEJ). The former is dependent on sequence
homology and is the most active in the late S/G2
phase. The latter uses little or no sequence homology,
which is sometimes imprecise and functions through-
out the cell cycle. NHEJ is therefore considered to be
the principal mechanism used in CSR, as AID-
dependent DSBs are introduced and repaired mainly
in the G1 phase of the cell cycle (Schrader et al. 2007)
and the nature of S region sequences (lack of long
stretches of perfect homology between the different S
regions) would theoretically not support HR.
The ‘classical’ NHEJ machinery requires a number
of factors, including Ku70/Ku80, DNA-dependent
protein kinase catalytic subunit (DNA-PKcs), DNA
ligase IV, XRCC4, Artemis and XLF (Cernunnos;
Lieber 2008). During the past decade, evidence has
accumulated that many of these factors are actually
required for the CSR process. When the classical
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NHEJ pathway is operative. In this paper, we will
review the current knowledge of the predominant
NHEJ pathway in CSR and give a perspective on the
alternative end-joining (A-EJ) mechanism.
2. THE PREDOMINANT NON-HOMOLOGOUS
END-JOINING PATHWAY DURING CLASS
SWITCH RECOMBINATION
The predominant end-joining pathway used in normal
cells during CSR requires not only components of
the classical NHEJ machinery, but also a number of
factors that are considered being DNA-damage
sensors, transducers or adaptors. Table 1 summarizes
the CSR phenotype in mouse knockout and human
disease models. A reduced efﬁciency of CSR and/or an
increased usage of microhomology at recombinational
junctions are common features when the predominant
NHEJ pathway is impaired (table 1).
(a) Ataxia-telangiectasia mutated signalling
(i) ATM
ATM is a phosphoinositol 3-kinase-like kinase (PIKK)
that plays a central role in orchestrating a network
of cellular responses to DSBs, including cell cycle
control, DNA repair and apoptosis (Shiloh 2003;
Lavin & Kozlov 2007). ATM deﬁciency in humans
results in a rare, multi-system disorder, ataxia–
telangiectasia (A–T), characterized by cerebellar
degeneration with ataxia, telangiectasia, chromosomal
instability, radiosensitivity and cancer predisposition
(Chun & Gatti 2004).
A–T is also recognized as a primary immuno-
deﬁciency disorder, with both the cellular and humoral
immune systems being affected, leading to recurrent
and severe infections (Lavin & Shiloh 1999). IgA
deﬁciency (IgAD) has been observed in 60–80% of
patients, and a subgroup suffers from concomitant IgG
subclass deﬁciency (Lavin & Shiloh 1999). During
investigations aimed at elucidating the underlying
cause of antibody deﬁciency in A–T patients, we
observed that the Sm–Sa recombination junctions in
patient B cells were characterized by a strong
dependence on short, perfectly matched sequence
homologies (microhomologies) and devoid of normally
occurring mutations around the breakpoints (Pan et al.
2002). More than 60 per cent of the junctions exhibited
a microhomology of 4 bp or more with the longest
being 21 bp, as illustrated in ﬁgure 1 in the very ﬁrst
set of breakpoints we obtained. This is far beyond
what one would expect as a consequence of NHEJ,
which should theoretically result in no, or a 1–3 bp,
microhomology. The serendipitous ﬁnding of an
aberrant pattern of Sm–Sa junctions from A–T patients
led us to hypothesize that ATM is involved in the
predominantly used NHEJ pathway in CSR. In A–T
patients, where ATM function is impaired, the S
regions are joined by an A-EJ pathway involving
microhomology (Pan et al. 2002). This concept was
not fully accepted at that time, as ATM was not
considered to be a part of the DSB repair machinery, in
particular not with NHEJ. Furthermore, deﬁnitive
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still missing.
ATM-deﬁcient mice have been generated in several
laboratories and these mice are characterized by growth
retardation, infertility, radiosensitivity and develop-
ment of thymic lymphomas (Barlow et al. 1996; Elson
et al. 1996; Xu et al. 1996). The serum level of
immunoglobulins is, however, largely normal (Xu et al.
1996) although reduced serum titres of antigen-speciﬁc
IgG and IgA antibodies have been detected after
immunization (Lumsden et al.2 0 0 4 ). Two studies
have subsequently shown that B cells from ATM-
deﬁcient mice cannot switch to IgG and IgA as
efﬁciently as do wild-type B cells, suggesting an intrinsic
B-cell defect during CSR (Lumsden et al.2 0 0 4 ;
Reina-San-Martin et al.2 0 0 4 ). Furthermore, the defect
is not due to alterations in cell proliferation, GL
transcription or 53BP1 focus formation and has thus
been suggested to be located either at an early step
referred to as synapsis, i.e. holding the DNA ends
S
(a)
(b)
(c)
(d)
(e)
AT1
S   1
AT2
AT3
AT4
AT5
S   2
S   1
S   1
S   1
S
S
S
S
Figure 1. The sequences of the ﬁrst ﬁve Sm–Sa junctions derived from A–T patients (Pan et al. 2002). The Sm and Sa1o rS a2
sequences are aligned above and below the recombined switch junctional sequences. Microhomology was determined by
identifying the longest region at the S junction of perfect uninterrupted donor/acceptor identity (solid-line boxes). Imperfect
repeats were determined by identifying the longest overlap region at the S junction by allowing one mismatch on either side of
the breakpoint (the extra nucleotide beyond the perfect matched sequence identity is indicated by dotted-line boxes). The Sm
and Sa breakpoints for each S fragment are indicated by a downward arrowhead and an upward arrowhead, respectively, and
their positions in the germ-line sequences (X54713, L19121 and AF030305; Mills et al. 1990; Islam et al. 1994; Pan et al. 2001)
are indicated above or below the arrowhead. (a) 21 bp microhomology (28/29 bp imperfect repeat), (b) 12 bp microhomology
(19/20 bp imperfect repeat), (c) 6 bp microhomology (9/10 bp imperfect repeat), (d) 7 bp microhomology (10/11 bp imperfect
repeat), (e) 7 bp microhomology (11/12 bp imperfect repeat).
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San-Martin et al. 2004), or at the break repair step
(Lumsden et al. 2004).
One of the two studies (Lumsden et al. 2004) has
also shown a signiﬁcant increase in the length of
microhomology at the Sm–Sg1 junctions (2.6 bp versus
1.2 bp in wild-type cells), not as dramatic as the Sm–Sa
junctions derived from A–T patients (7.2 bp versus
1.8 bp in controls), but very similar to the Sm–Sg
junctions from these patients (2.5 bp versus 1.2 bp in
controls; Pan et al.2 0 0 2 ). As we have discussed
previously (Pan-Hammarstrom et al. 2007), and will
present in more detail later, Sm–Sa and Sm–Sg
junctions are resolved differently both under normal
circumstances and in patients with various defects in
their DNA repair systems. Owing to the higher degree
of homology between Sm and Sa when compared with
Sm and Sg, the microhomology-based pathway would
be a more attractive alternative for Sm/Sa recombina-
tion when the classical NHEJ pathway is impaired.
Thus, we would probably observe a more dramatic
shift in the use of longer microhomologies in ATM-
deﬁcient mouse B cells if the Sm–Sa junctions were
analysed. It is currently unclear though, whether a
‘normal’ appearance of Sm–Sg junctions, i.e. a normal
length of microhomology, would simply indicate a
normal end joining or whether it may actually result
from yet another A-EJ mechanism that does not require
a long microhomology.
The exact function of ATM in the predominant
NHEJ pathway in CSR remains unclear. ATM
phosphorylates a number of factors that are known to
be involved in CSR, including NBS1, Mre11, gH2AX,
53BP1 and MDC1. Thus, one possible role of ATM is
to recruit and/or activate other DNA-damage response
factors, such as gH2AX, 53BP1, MDC1 and possibly
the Mre11 complex, conﬁguring the DNA termini for
subsequent repair steps, and/or slowing down cell cycle
progression until the repair is complete (Lieber 1999;
Lieber et al. 2003; ﬁgure 2). As we will discuss below,
however, the CSR phenotype resulting from deﬁciency
of any of these ATM substrates is clearly not identical
to a deﬁciency of ATM (table 1). A second possibility is
that ATM may have a more direct role in the end-
processing step through phosphorylation of a proposed
nuclease that participates in NHEJ, i.e. Mre11 or
Artemis (ﬁgure 2). Artemis would be an interesting
candidate, as it is a downstream component in the
ATM signalling pathway required for the repair of a
subset of radiation-induced DSBs, but dispensable for
ATM-dependent cell-cycle checkpoint arrest (Riballo
et al. 2004). Artemis, however, appears to be dis-
pensable for efﬁcient CSR (Rooney et al.2 0 0 5 ),
although a recent study has provided evidence that
Artemis is required for repair of at least part of the
CSR-related chromosomal breaks at the Ig locus
(Franco et al. 2008). Finally, a recent, large-scale
proteomic analysis has identiﬁed an impressive list of
ATM and ATR substrates (nZ700), including some
additional factors that have previously been implicated
in CSR, such as the mismatch repair factors MSH2,
MSH6, MLH1, PMS2, EXO1 and RPA1 (Matsuoka
et al. 2007). An increased length of microhomology at
Sm–Sg junctions has indeed been observed in MLH1
and PMS2 knockout mice (Ehrenstein et al. 2001;
Schrader et al. 2002), supporting a potential link
between ATM/ATR and the mismatch repair factors.
(ii) gH2AX (phosphorylated H2AX)
In response to DNA DSBs by ionizing radiation,
H2AX is rapidly phosphorylated by ATM or DNA-
PKcs (Burma et al. 2001; Hickson et al.2 0 0 4 ),
resulting in the formation of gH2AX foci that spread
throughout a megabase-long region ﬂanking the break
(Rogakou et al. 1999). In cells undergoing CSR, NBS1
and gH2AX foci are formed and co-localized at the CH
region during the G1 phase of the cell cycle, suggesting
that these factors might also have a role in response to
CSR-induced DSBs (Petersen et al. 2001).
H2AX-deﬁcient mice are growth retarded, immuno-
deﬁcient, radiosensitive and show male-speciﬁc inferti-
lity (Celeste et al. 2002). Serum levels of IgG1, IgG3
and IgA are signiﬁcantly reduced in these mice and
in vitro CSR to IgG1 and IgG3 is markedly reduced
(approx. 25–30% of wild-type levels; Petersen et al.
2001; Celeste et al. 2002). The impaired CSR in
H2AX-deﬁcient cells is not due to an alteration in
induction of GL transcription and short-range
intra-switch region recombination proceeds normally
(Reina-San-Martin et al. 2003). The pattern of Sm–Sg1
junctions is also largely normal, with a normal length of
microhomology at the junctions and only a slightly
reduced frequency of mutations around the junctions
(Reina-San-Martin et al. 2003). The role of gH2AX in
CSR has therefore been proposed to facilitate
long-range synapsis of two different S regions (Reina-
San-Martin et al. 2003). A recent study has further
shown that AID-dependent IgH locus chromosome
breaks occur at a high frequency in H2AX-deﬁcient B
cells undergoing CSR, suggesting that gH2AX may
promote end joining during CSR (Franco et al. 2006).
Interestingly, activated B cells deﬁcient in ATM,
53BP1 or MDC1 show a similar phenotype, with an
increased number of IgH locus breaks and transloca-
tions (Franco et al. 2006), implying that they may have
a common function in the predominant NHEJ pathway
in CSR. However, the largely normal pattern of Sm–Sg
junctions in H2AX-deﬁcient cells argues against the
idea but, as we have discussed above, analysis of Sm–Sa
junctions in these cells will be required before it is
deﬁned as normal. Alternatively, ATM and gH2AX, or
53BP1 (as discussed below), play additional roles
in CSR, which are independent of each other.
(iii) MDC1
MDC1, yet another ATM substrate (Goldberg et al.
2003; Lou et al. 2003; Stewart et al. 2003), is a
mediator or adaptor that mediates gH2AX-dependent
chromatin retention of DNA-damage response factors
(Stucki & Jackson 2006). MDC1-deﬁcient mice show
similar phenotypes as H2AX-deﬁcient mice, including
growth retardation, male infertility, immunodeﬁciency,
chromosomal instability and radiosensitivity (Lou et al.
2006). Serum levels of immunoglobulins are normal
in MDC1-deﬁcient mice, and a reduction in CSR
to approximately 50–75% of wild-type levels has
been observed in cultured MDC1-deﬁcient B cells
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not analysed in these cells.
(iv) 53BP1
53BP1 was ﬁrst identiﬁed as a p53-binding protein
(Iwabuchi et al. 1994) and later shown to participate at
an early stage in DNA DSB signalling (Schultz et al.
2000; DiTullio et al. 2002; Fernandez-Capetillo et al.
2002; Wang et al. 2002). 53BP1 is phosphorylated by
ATM but may also be an activator of ATM in response
to DNA DSBs (for review see Mochan et al. 2004).
53BP1-deﬁcient mice are growth retarded, radio-
sensitive, immunodeﬁcient and predisposed to cancer
(Ward et al. 2003), a phenotype that resembles ATM or
H2AX knockout mice. Studies on 53BP1-deﬁcient
mice have further demonstrated that 53BP1 is
dispensable for HR, variable diversity joining (V(D)J)
recombination and somatic hypermutation (SHM)
but is clearly required for CSR (Manis et al. 2004;
Ward et al. 2004). Serum levels of IgG and IgA are
substantially reduced (Manis et al. 2004) and the ability
of 53BP1-deﬁcient B cells to switch in vitro, to all the
isotypes, is severely impaired (reduced to 2–10% of
wild-type levels; Manis et al. 2004; Ward et al. 2004).
The CSR defect is not due to a proliferative block or
an alteration of GL transcription (Manis et al. 2004;
Ward et al. 2004) and the Sm–Sg1 junctions reveal
no signiﬁcant differences in the length of microhomol-
ogy or mutation frequency (Manis et al. 2004;
Reina-San-Martin et al.2 0 0 7 ). However, unusual
long insertions, not seen in 240 S junctions from
wild-type cells, have been observed in two Sm–Sg1
53BP1
K/K junctions, and intra-switch recombination
is enhanced in 53BP1-deﬁcient cells (Reina-San-
Martin et al. 2007), suggesting a potential role of
53BP1 in synapsis or protecting the DNA ends of the
two S regions.
There is thus far no human disease that has been
linked to mutations in the gene encoding 53BP1. A
recent study has, however, described a patient who
suffered from the RIDDLE syndrome (radiosensitivity,
immunodeﬁciency, dysmorphic features and learning
difﬁculties; Stewart et al. 2007). Cells from this patient
lack an ability to recruit 53BP1 to the sites of DNA
DSBs. Mutations were neither found in the gene
encoding 53BP1 itself nor in the genes encoding
ATM, MDC1, H2AX and PR-Set7, factors that are
known to be involved in regulating the localization of
53BP1 to the breaks (Stewart et al. 2007). It is possible
that an as yet unknown protein, acting upstream of
53BP1 during the cellular response to DNA DSBs, is
defective in this patient. It is interesting to note that
signiﬁcantly increased microhomology is observed at
the Sm–Sa junctions ampliﬁed from this patient, with
94 per cent of junctions exhibiting a microhomology of
4b p o r m o r e ( Stewart et al. 2007). A reduced
frequency of insertions and mutations around the
Sm–Sa breakpoints is also observed. The Sm–Sg3
junctions from this patient have also been analysed,
albeit unfortunately not shown in the paper.
AID (a)( b) AID
Ku70/Ku80
ATM
/ATR
DNA-PKcs
Mre11/Rad50/NBS1?
XLF?
XRCC4
DNA ligase IV
UNG
MSH2
Artemis?
DNA-PK? XRCC1?
DNA ligase III?
Mre11/Rad50/NBS1?
ATM
ATR?
AID AID
UNG
MSH2
γH2AX
MDC1
53BP1
PARP-1?
WRN?
microhomology
Figure 2. Hypothetical model for the end-joining mechanisms during CSR. AID initiates CSR, probably through deamination
of deoxycytidine (dC) residues in the S regions. The dC:dU mismatches can then be processed by either the MSH2-dependent
mismatch repair pathwayor the UNG-dependent base excision repair, leading to the production of DSBs in the S regions. In the
predominant NHEJ pathway, Ku70/Ku80 binds to DNA ends and recruits and activates DNA-PKcs. They are probably
important for the synapsis process. ATM and ATM-dependent factors gH2AX, MDC1 and 53BP1 are required for the
predominant NHEJ pathway, probably at the synapsis or end-activation step. Together they may be conﬁgurating the DNA
termini for subsequent repair steps and/or regulating the cell cycle response. ATM may also have a direct role in the end-
processing step by phosphorylation of Artemis, a nuclease that may have the potential to repair a subset of DSBs in CSR. The
Mre11 complex may be involved in CSR either by activating ATM and/or as a nuclease that is required for the microhomology-
mediated end joining. Finally, XRCC4/DNA ligase IVand possibly XLFare involved in the ligation step. The factors involved in
the A-EJ are not knownbut a few candidates are highlighted in the ﬁgure (indicated by question marks). (a) Predominant NHEJ,
(b) alternative end joining.
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this patient suggests that there could be a shift from the
dominant NHEJ to the A-EJ pathway when the
formation of 53BP1 foci is defective.
The precise role of 53BP1 in CSR remains elusive.
The CSR defect observed in 53BP1-deﬁcient mice is
more severe than that in ATM- or H2AX-deﬁcient
mice, and the pattern in the Sm–Sg junctions is different
from that of ATM-deﬁcient cells (although Sm–Sa
junctions have not been analysed in 53BP1-deﬁcient
mice). It is thus likely that in addition to being part of
the ATM signalling pathway, 53BP1 also has a role in
CSR, which is independent of ATM or gH2AX. A
recent study has shown that MDC1 functions primarily
in HR/sister chromatic recombination, in a manner
that is strictly dependent upon its ability to interact
with gH2AX, whereas 53BP1 functions in an XRCC4-
dependent NHEJ pathway, through interaction with
the dimethylated lysine 20 of histone H4, a process
that is independent of gH2AX (Xie et al. 2007). If this
is also true for CSR, it would probably explain why
CSR is affected in the order of 53BP1
K/K more than
H2AX
K/K more than MDC1
K/K.
(v) The Mre11–Rad50–NBS1 complex
The Mre11 complex is a multisubunit nuclease
composed of Mre11, Rad50 and NBS1. This complex
is required for telomere maintenance, cell-cycle
checkpoint signalling, DNA replication, meiotic
recombination and efﬁcient repair of DNA DSBs by
HR and/or NHEJ (D’Amours & Jackson 2002; Lavin
2007). The Mre11 complex acts as a sensor of DNA
DSBs, localizes to the sites of break and recruits ATM
(Berkovich et al. 2007; Lavin 2007). This will lead to
autophosphorylation and activation of ATM, which in
turn will phosphorylate many substrates, including
members of the Mre11 complex. The Mre11 complex
thus acts both upstream and downstream of ATM. In
humans, no mutations in Rad50 have been reported to
date. Mutations in genes encoding Mre11 and NBS1
result in two chromosomal instability syndromes,
ataxia–telangiectasia-like disorder (ATLD; Stewart
et al. 1999) and Nijmegen breakage syndrome (NBS;
Varon et al. 1998), where both exhibit features that are
characteristic for A–T.
NBS patients are characterized by immuno-
deﬁciency, microcephaly, chromosomal instability and
a high incidence of lymphoid malignancies (Digweed &
Sperling 2004). Deﬁciency of IgG and/or IgA is
observed in 80–90% of the patients (Gregorek et al.
2002), which could be due to a lack of T-cell help and/
or an intrinsic B-cell defect. By analysing the in vivo-
switched B cells, we have previously shown a reduced
level of CSR to IgA in NBS patients (Pan et al. 2002).
The recovered Sm–Sa and Sm–Sg junctions also show a
signiﬁcantly increased length of microhomology,
although not as dramatic as those derived from A–T
patients (Pan et al. 2002; table 1). In contrast to A–T
and NBS patients, normal immunoglobulin levels are
observed in most ATLD patients described to date
(Stewart et al. 1999; Delia et al. 2004; Fernet et al.
2005). Signiﬁcantly reduced numbers of Sm–Sa and
Sm–Sg clones have, however, also been shown in ATLD
patients (Lahdesmaki et al. 2004). There is a trend (not
signiﬁcant) in the use of longer microhomologies at the
Sm–Sa junctions but not in the Sm–Sg junctions. The
dependence of microhomology at the Sm–Sa or Sm–Sg
junctions is thus A–TONBSOATLDOcontrol.
The Sm–Sa junctions obtained from NBS and
ATLD patients are, however, clearly different from
those in A–T patients, in at least two respects: ﬁrst, the
blunt end direct joining mechanism (requiring no
microhomology) is severely impaired in A–T patients
but not in NBS or ATLD patients. Second, the precise
joining of complementary DNA ends with 1–3 bp
sequence homology, probably executed through a
simple religation mechanism (Haber 1999), is normal
in A–T patients, but defective in NBS and, to a lesser
degree, ATLD patients. Mutations or insertions often
occur at junctions with 1–3 bp microhomology in NBS
and ATLD patients (Lahdesmaki et al. 2004). Thus, as
in cells from A–T patients, the balance between the
predominantly used NHEJ and the A-EJ pathways is
altered. ATM and the Mre11 complex may, however,
act on the predominant end-joining pathway in a
different manner or at a different step (Pan et al. 2002;
Lahdesmaki et al. 2004). NBS1 and Mre11 may also
have roles in CSR, which are independent of each
other, as the patterns of mutations and insertions
around the Sm–Sa junctions are clearly different. In
NBS patients, all base substitutions were located at
G/C nucleotides, and in ATLD patients, the sub-
stitutions that occurred most often in controls, C to T
transitions, were never observed (Lahdesmaki et al.
2004). These peculiar patterns of base substitutions
are, however, speciﬁc for the CSR reactions, as they are
quite different from the SHM patterns we observed in
the VH regions from these patients (Du et al. 2008).
In mice, disruption of any subunit of the Mre11
complex results in embryonic lethality (Xiao & Weaver
1997; Luo et al. 1999; Zhu et al. 2001). A humanized
mouse model for NBS has been generated by the
introduction of the human 5 bp deletion hypomorphic
allele into NBS-deﬁcient mice (Diﬁlippantonio et al.
2002). No CSR defect (to IgG1 and IgG3) has,
however, been observed in this mouse model. Using a
conditional knockout strategy, two studies have shown
that CSR to various IgG subclasses is reduced in
NBS1-deﬁcient B cells (to approx. 50% of wild-type
levels; Kracker et al. 2005; Reina-San-Martin et al.
2005). The CSR defect is not dependent on GL
transcription and appears to be due to inefﬁcient
recombination at the DNA level (Reina-San-Martin
et al. 2005). In both studies, a normal length of
microhomology and a normal rate of mutations were
found at the Sm–Sg junctions. It is noteworthy that in
one of the studies, residual levels of wild-type NBS
(25%) remained in the cells, and thus the effect of
NBS1 on CSR may well have been underestimated
(Kracker et al. 2005) as some CSR junctions might be
derived from NBS-proﬁcient cells. The level of IgA
switching and the quality of Sm–Sa junctions have not
been analysed to date in these mice.
(vi) ATR
As discussed earlier, the CSR defect in 53BP1-deﬁcient
cells is even more severe than that in ATM-deﬁcient
cells. Another possibility is that additional upstream
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CSR. The A–Tand Rad3-related protein (ATR) could
be one such candidate, as it is closely related to ATM
and targets an overlapping set of substrates, including
53BP1 and H2AX (Abraham 2001; Cimprich &
Cortez 2008). Loss of ATR in mice results in
embryonic lethality (Brown & Baltimore 2000)
whereas hypomorphic mutations in the ATR gene
have been identiﬁed in a few patients with the Seckel
syndrome (O’Driscoll et al. 2003). These patients are
characterized by intrauterine growth retardation,
dwarﬁsm, microcephaly, ‘bird-like’ facial features and
mental retardation but no obvious immunodeﬁciency.
Studies on B cells from these patients have shown that
the proportion that has switched to IgA and IgG in the
peripheral blood is normal (Pan-Hammarstrom et al.
2006). An analysis of the Sm–Sa junctions showed a
normal ‘blunt end-joining’ and a normal ‘simple
religation’ process (joining 1–3 bp complementary
ends), but impaired end joining with partially comp-
lementary (1–3 bp) DNA ends. There is also a
signiﬁcant increase in the length of microhomology at
the Sm–Sa junctions (3.0 bp versus 1.8 bp in controls),
but only up to 9 bp. Thus, ATR is likely to have a
moderate role in the predominant end-joining process
during CSR. Whether this is due to its interaction with
53BP1 or gH2AX is, however, unknown. An additional
speculation is that ATR may also be required in the
A-EJ pathway where a longer microhomology (10 bp
or more) is required (ﬁgure 2).
(b) The classical non-homologous end
joining machinery
(i) Ku70/Ku80
Ku is a heterodimer of Ku70 and Ku80. They are
probably among the ﬁrst proteins that bind to the DNA
ends at a DSB and the Ku–DNA complex recruits
and activates DNA-PKcs (Lieber et al. 2003; Lieber
2008). Ku and DNA-PKcs are proposed to act in the
synapsis process (Lieber et al. 2003; Lieber 2008).
Ku70 or Ku80 knockout mice are growth retarded,
radiosensitive and are severely immunodeﬁcient
(Nussenzweig et al. 1996; Gu et al. 1997). B-cell
development is arrested at an early stage due to
a profound deﬁciency in V(D)J recombination
(Nussenzweig et al. 1996; Gu et al. 1997). To assess
the role of Ku in CSR, pre-rearranged V(D)J heavy
chain and VJ light chain genes were introduced into a
Ku70- or Ku80-deﬁcient background. In both cases,
CSR to IgG and/or IgE is severely impaired, suggesting
that the Ku heterodimer is required for CSR (Casellas
et al. 1998; Manis et al. 1998). However, the severe
proliferation defect of Ku-deﬁcient B cells has made it
difﬁcult to determine whether Ku, and thus NHEJ, has
a direct role in end joining during CSR. No CSR
junctions have been analysed in Ku70- or Ku80-
deﬁcient mice. However, the majority of the recovered
coding or RS joints from Ku70-deﬁcient cells exhibited
1–5 bp short homologies (Gu et al. 1997).
(ii) DNA-PKcs
The ﬁrst piece of evidence that DNA-PKcs might be
involvedinCSR camefromastudy usingpre-B celllines
derived from severe combined immunodeﬁciency
(Scid) mice, where the ability of these lines’ switch to
IgE was impaired (Rolink et al. 1996). These mice carry
a spontaneous point mutation in the DNA-PKcs gene,
which results in a truncated protein lacking DNA-PKcs
kinase activity (Blunt et al.1 9 9 6 ; Danska et al.1 9 9 6 ;
Beamish et al.2 0 0 0 ). In a second study, Ig heavy and
light chain knock-in DNA-PKcs-null mice were ana-
lysed and, despite a normal proliferation, GL transcrip-
tion and AID induction, CSR to all the Ig classes was
severely impaired, with the exception of IgG1, providing
convincing evidence that DNA-PKcs is required for
CSR (Manis et al.2 0 0 2 ). The importance of DNA-
PKcs in CSR has, however, been challenged by studies
where Ig heavy and light chain knock-in Scid (Bosma
et al. 2002; Cook et al.2 0 0 3 ) or DNA-PKcs C-terminal
deleted mice (Kiefer et al. 2007) were analysed. CSR
efﬁciency was either close to normal (Kiefer et al. 2007)
or reduced approximately two- tothreefold (Bosma etal.
2002; Cook et al.2 0 0 3 ). The difference between the
DNA-PKcs-null and Scid mice may suggest that the
kinase activity of DNA-PKcs is not essential, or at least
replaceable, during CSR, and DNA-PKcs may have a
non-catalytic role in CSR, for instance by mediating
synapse complex formation (DeFazio et al. 2002).
Based on the Scid studies, one can imagine a DNA-
PKcs kinase-independent end-joining process in CSR.
It would be of interest to know whether this is still part
of NHEJ or it is the A-EJ used in the absence of ATM.
In DNA-PKcs-null cells, the Sm–Sg1 junctions appear
to be indistinguishable from controls (Manis et al.
2002). In one of the studies on Scid mice, CSR
junctions have been analysed and a small increase in
microhomology usage has been observed (3.4 bp
versus 2.3 bp; Cook et al. 2003). However, this was
based on a mixture of junctions (Sm–Sg,S g–S3 and
Sm–S3). As Sm–S3 junctions, similar to Sm–Sa, tend to
show longer microhomologies when NHEJ is impaired
(Pan-Hammarstrom et al. 2005; Yan et al. 2007), this
analysis is not conclusive. A separate analysis of
different types of CSR junctions would be preferable.
The pattern of mutations around these CSR junctions
is, however, altered, with a signiﬁcantly reduced
number of C mutations (resembling those from
ATLD patients), suggesting that the kinase activity of
DNA-PKcs may have a role in the later steps of the
end-joining process during CSR. This notion is also
supported by a recent study showing that DNA-PKcs is
required for end joining of a subset of AID-induced
CSR breaks (Franco et al. 2008).
(iii) DNA ligase IVand XRCC4
The XRCC4–DNA ligase IV complex is responsible for
catalysing the ligation step of NHEJ (Lieber et al. 2003;
Lieber 2008). No human disease has yet been shown to
be associated with a mutation in the XRCC4 gene,
whereas a few patients with defective DNA ligase IV
activity have been described. These patients are
characterized by microcephaly, growth retardation,
radiosensitivity and mild to severe immunodeﬁciency
(O’Driscoll et al. 2001; Buck et al. 2006; Enders et al.
2006; van der Burg et al. 2006). CSR junctions have
been characterized in some of these patients and a
marked shift to the usage of microhomology at the
Sm–Sa junctions has been observed (9.8 bp versus
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This shift is most dramatic among all the patient groups
that we have tested to date (DNA ligase IVOATMO
NBSOATROATLD). Almost all junctions (97%)
displayed at least 1 bp microhomology, the remaining
being 1 bp insertions, thus the ‘blunt end joining’ or
‘direct end joining’ is completely abolished in the DNA
ligase IV-deﬁcient cells. Forty-seven per cent of the
junctions exhibited a microhomology of 10 bp or more
with the longest being 29 bp, which is by far the longest
that has been described in human cells. A reduction
of mutations or insertions at, or around, the Sm–Sa
junctions was also observed.
Despite the dramatic increase of microhomology at
the Sm–Sa junctions, the Sm–Sg junctions only show an
increased frequency of insertions, but no signiﬁcant
increase in the length of junctional homology or rate
of mutations (Pan-Hammarstrom et al. 2005). This
difference cannot solely be due to differences in the
homology between the Sm and the Sa or Sg regions, as a
small, albeit signiﬁcant, increased length of microho-
mology has been observed in the Sm–Sg junctions from
ATM-, ATR- and NBS-deﬁcient cells. Furthermore, no
signiﬁcant increase in the rate of insertions has been
observedat theSm–Sgjunctionsfrom thesepatients.Itis
possible that yet another alternative pathway is used for
joining theSm–Sg regionsinthe DNAligaseIV-deﬁcient
patients, where 1 bp insertions are frequently intro-
duced. It is also possible that the residual level of DNA
ligase IV activity in the patient cells results in different
modes of CSR junction resolution.
Disruption of LIG4 or XRCC4 in mice results in
embryonic lethality. Models that are based on XRCC4-
deﬁcient-mouse B cells have therefore been generated
by two independent groups using different strategies
(Soulas-Sprauel et al. 2007; Yan et al. 2007). CSR to
IgG or IgE is reduced to approximately 20–50% of
control levels in XRCC4-deﬁcient cells (Soulas-
Sprauel et al. 2007; Yan et al. 2007). In one of the
studies, Yan et al. (2007) analysed Sm–Sg and Sm–S3
junctions and demonstrated that there is a shift towards
microhomology-based, alternative joining in the
absence of XRCC4. They also found that ‘blunt’ or
‘direct’ end joining is totally abolished in XRCC4-
deﬁcient cells. In their preliminary studies, they have
also observed a similar lack of direct joining and a bias
towards a microhomology-based joining in DNA ligase
IV-deﬁcient mouse B cells. These results, taken
together with the data obtained from DNA ligase
IV-deﬁcient patients, clearly suggest that the classical
NHEJ machinery is required for CSR and, in its
absence, an A-EJ mechanism is operating.
(c) Additional factors
Increased microhomology at the CSR junctions has also
been observed in mice deﬁcient in PMS2, MLH1,
MSH4 or MSH5 and in IgAD and common variable
immunodeﬁciency (CVID) patients carrying mutations
intheMSH5gene(Ehrensteinetal.20 01 ;Schrader etal.
2002; Sekine et al.2 0 0 7 ; Pan-Hammarstrom &
Hammarstrom 2008). How the different mismatch
repair pathways are connected to the NHEJ machinery
is currently unclear. In addition to the patient who
suffered from the RIDDLE syndrome, a marked shift
towards microhomology at the Sm–Sa junctions has also
been observed in several patients suffering from another
rare form of immunodeﬁciency (hyper IgM syndrome)
with an unknown genetic basis (Peron et al.2 0 0 7 ).
The predominant NHEJ pathway in CSR is thus likely
to be regulated by additional DNA-damage response/
repair factors that remain to be characterized.
3. THE ALTERNATIVE END-JOINING PATHWAY
DURING CLASS SWITCH RECOMBINATION
The A-EJ mechanism used in CSR and V(D)J
recombination (Corneo et al. 2007) also contributes
to the chromosomal translocations that give rise to
lymphoid malignancies (Nussenzweig & Nussenzweig
2007; Yan et al. 2007). Compared with the predomi-
nant NHEJ pathway, however, we know rather little
about the mechanism underlying A-EJ. Deletions,
insertions and microhomologies are normally associ-
ated with the A-EJ pathway; however, we do not know
the kinetics of the repair (fast or slow), during which
cell cycle it is operative (G1 or others), how long
a microhomology that is required (more than 1 bp,
or 4 bp or even longer), whether there is only one or
multiple pathways or the identity of the factors actually
involved in the A-EJ mechanism. The identiﬁcation of
the factors in the A-EJ pathway may be complicated
by the possibility that a short microhomology could
be the result of either the NHEJ or A-EJ pathways,
whereas lack of microhomology may not necessarily
exclude the involvement of A-EJ. Furthermore, some
factors regulating the classical NHEJ pathway may also
be involved in the A-EJ process. A number of potential
factors of the latter will be brieﬂy discussed below.
(a) The Mre11–Rad50–NBS1 complex
The 30–50 exonuclease activity of Mre11 has previously
been suggested to be involved in microhomology-based
end joining, where it degrades the mismatched DNA
ends until sequence identity is revealed (Paull & Gellert
2000). Based on the CSR junctions from ATLD and
NBS patients, we have previously hypothesized that the
Mre11 complex may be required for repairing DNA
ends with a short (1–3 bp) homology, which is likely to
be part of the NHEJ reaction. The Mre11 complex is,
however, unlikely to be involved in A-EJ,if this pathway
requires microhomology of 4 bp or longer, as the pro-
portion of junctionswith these longer microhomologies
is slightly increased, rather than decreased, in both
patient groups (Lahdesmaki et al. 2004).
(b) Poly (ADP-ribose) polymerase 1, XRCC1
and DNA ligase III
Poly (ADP-ribose) polymerase 1 (PARP-1) is an
abundant nuclear protein that binds to both single-
strand breaks (SSBs) and DSBs. It is involved in many
cellular responses including base excision repair (BER)
and, possibly, HR (Helleday et al. 2005). Together with
XRCC1 and DNA ligase III, it has also been proposed
as a candidate factor for the alternative, or back-up,
pathway of NHEJ (Audebert et al. 2004; Wang et al.
2005, 2006). PARP-1 binds to DNA ends and, under
normal conditions, it is in direct competition with Ku
and possibly also DNA-PKcs (Wang et al. 2006).
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switching in a B cell line and enhance IgG1 switching in
activated splenic B cells (Shockett & Stavnezer 1993).
This may imply that PARP-1 would normally inhibit
or compete with other factors that participate in the
predominant NHEJ pathway during CSR, which ﬁts
well with the hypothesis that it may be a component of
the A-EJ pathway. Inhibitors of PARP-1 can in fact lead
to the activation of ATM in other DNA repair process
such as HR (Bryant & Helleday 2006). It would
therefore be of considerable interest to test the effect of
PARP-1 in CSR on an NHEJ-deﬁcient background.
Both ligases I and III seem to be required for
microhomology-mediated end joining (Liang et al.
2008) but which of the two ligases is involved in A-EJ
during CSR remains to be clariﬁed.
(c) Werner protein
Werner protein (WRN) belongs to the RecQ helicase
family and is mutated in the premature ageing disease,
Werner’s syndrome (Yu et al.1 9 9 6 ). WRN has been
implicated in HR but has also been linked to NHEJ, as
its exonuclease activity is stimulated by Ku70/Ku80
(Li & Comai 2000). WRN, together with ligase III, has
recently been implicated in A-EJ activity in chronic
myeloid leukaemia cells, where knockdown of these
factors leads to a signiﬁcant reduction of microho-
mologyattherepair sites(Sallmyretal. 2008).However,
WRN physically interacts with one of the key NHEJ
factors, the XRCC4–DNA ligase IV complex, which
stimulates WRN’s exonuclease activity (Kusumoto et al.
2008). Thus, it is unclear which pathway WRN is
actually involved in during CSR (if it has a role at all).
4. CONCLUDING REMARKS
Over the past decade, we have begun to understand the
complex molecular mechanisms underlying DNA
editing, repair and recombination during CSR. Two
major repair pathways have been proposed, the
predominant NHEJ and the A-EJ involving micro-
homologies (ﬁgure 2). A more complicated picture will
probably emerge when the NHEJ pathway is further
dissected and the A-EJ pathway is delineated. The
ultimate goal will be to have a three-dimensional
dynamic model for CSR, where we would know the
molecular basis of the process and the interaction
between the DNA repair factors at the switch regions.
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